US drug approvals
2 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- See reportsGrowth in full reports
Free public data on Seattle Genetics
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Website
- seattlegenetics.com
- Home country
- United States
- Stock listing
- NASDAQ: SGEN
- Type
- Medicines
See them on openFDA (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1060736.
Markets where public records show them
Markets we cover where free public records show Seattle Genetics: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Seattle Genetics is in.
From our blog
Stories on the topics Seattle Genetics works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Bioinformatics: Making Sense of Health Data
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read